XILIO DEVELOPMENT INC
NASDAQ: XLO (Xilio Therapeutics, Inc.)
最近更新时间: 22分钟之前8.93
-0.06 (-0.72%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Xilio Therapeutics, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.07 |
|
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 45.76% |
| 机构持股比例 | 22.99% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Bain Capital Life Sciences Investors, Llc | 30 Jun 2026 | 664,021 |
| Gilead Sciences, Inc. | 30 Jun 2026 | 650,389 |
| Orbimed Advisors Llc | 30 Jun 2026 | 592,300 |
| Frazier Life Sciences Management, L.P. | 30 Jun 2026 | 422,505 |
| Stonepine Capital Management, Llc | 30 Jun 2026 | 225,994 |
| Vanguard Capital Management Llc | 30 Jun 2026 | 178,517 |
| Sio Capital Management, Llc | 30 Jun 2026 | 152,464 |
| Adage Capital Partners Gp, L.L.C. | 30 Jun 2026 | 111,541 |
| Merck & Co., Inc. | 30 Jun 2026 | 105,982 |
| Vanguard Group Inc | 31 Dec 2025 | 89,694 |
| Renaissance Technologies Llc | 30 Jun 2026 | 64,153 |
| Morgan Stanley | 30 Jun 2026 | 56,954 |
| Aju Ib Investment Co., Ltd. | 31 Mar 2026 | 47,695 |
| Geode Capital Management, Llc | 30 Jun 2026 | 39,055 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合